Intellia Therapeutics (NTLA) Stock Forecast & Price Target

→ Can't believe it's happening again (From Manward Press) (Ad)

$21.81

-1.11 (-4.84%)

(As of 04/16/2024 ET)

Intellia Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 13 Analyst Ratings

Analysts' Consensus Price Target

$67.00
207.20% Upside

High Forecast	$107.00
Average Forecast	$67.00
Low Forecast	$29.00

Type	Current Forecast 4/17/23 to 4/16/24	1 Month Ago 3/18/23 to 3/17/24	3 Months Ago 1/17/23 to 1/17/24	1 Year Ago 4/17/22 to 4/17/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	12 Buy rating(s)	16 Buy rating(s)	16 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$67.00	$66.93	$75.47	$85.67
Predicted Upside	207.20% Upside	114.23% Upside	128.22% Upside	116.11% Upside

Get Intellia Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

NTLA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NTLA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Intellia Therapeutics Stock vs. The Competition

Type	Intellia Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.69	2.68	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	202.62% Upside	1,012.41% Upside	11.49% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
2/23/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$72.00 ➝ $73.00	+176.72%
2/23/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$136.00 ➝ $32.00	+17.73%
2/15/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$29.00	+1.86%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
11/13/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$80.00 ➝ $70.00	+197.37%
11/13/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$90.00 ➝ $85.00	+266.54%
11/10/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$78.00 ➝ $57.00	+136.22%
11/10/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$80.00 ➝ $70.00	+189.14%
11/10/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$64.00 ➝ $62.00	+156.09%
9/13/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00	+76.97%
8/7/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$107.00	+170.13%
8/4/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$148.00 ➝ $90.00	+125.06%
8/4/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$44.00 ➝ $40.00	+2.33%
6/13/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$89.00 ➝ $91.00	+106.77%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:06 PM ET.

NTLA Price Target - Frequently Asked Questions

What is Intellia Therapeutics's consensus rating and price target?: According to the issued ratings of 13 analysts in the last year, the consensus rating for Intellia Therapeutics stock is Moderate Buy based on the current 4 hold ratings and 9 buy ratings for NTLA. The average twelve-month price prediction for Intellia Therapeutics is $67.00 with a high price target of $107.00 and a low price target of $29.00. Learn more on NTLA's analyst rating history.
Do Wall Street analysts like Intellia Therapeutics more than its competitors?: Analysts like Intellia Therapeutics more than other Medical companies. The consensus rating score for Intellia Therapeutics is 2.69 while the average consensus rating score for medical companies is 2.68. Learn more on how NTLA compares to other companies.
Is Intellia Therapeutics being downgraded by Wall Street analysts?: Over the previous 90 days, Intellia Therapeutics's stock had 1 downgrade by analysts.

Does Intellia Therapeutics's stock price have much upside?: According to analysts, Intellia Therapeutics's stock has a predicted upside of 121.13% based on their 12-month stock forecasts.
What analysts cover Intellia Therapeutics?: Intellia Therapeutics has been rated by Canaccord Genuity Group, The Goldman Sachs Group, Wedbush, and Wolfe Research in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:NTLA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

Intellia Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

NTLA Analyst Ratings By Month

NTLA Price Targets by Month

Intellia Therapeutics Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

NTLA Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info